246 related articles for article (PubMed ID: 15688284)
1. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
[TBL] [Abstract][Full Text] [Related]
2. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
Durbin AP; McArthur J; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
Hum Vaccin; 2006; 2(4):167-73. PubMed ID: 17012875
[TBL] [Abstract][Full Text] [Related]
3. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
[TBL] [Abstract][Full Text] [Related]
5. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.
Simasathien S; Thomas SJ; Watanaveeradej V; Nisalak A; Barberousse C; Innis BL; Sun W; Putnak JR; Eckels KH; Hutagalung Y; Gibbons RV; Zhang C; De La Barrera R; Jarman RG; Chawachalasai W; Mammen MP
Am J Trop Med Hyg; 2008 Mar; 78(3):426-33. PubMed ID: 18337339
[TBL] [Abstract][Full Text] [Related]
7. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Hanley KA; Manlucu LR; Manipon GG; Hanson CT; Whitehead SS; Murphy BR; Blaney JE
Vaccine; 2004 Sep; 22(25-26):3440-8. PubMed ID: 15308370
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
McArthur JH; Durbin AP; Marron JA; Wanionek KA; Thumar B; Pierro DJ; Schmidt AC; Blaney JE; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2008 Nov; 79(5):678-84. PubMed ID: 18981503
[TBL] [Abstract][Full Text] [Related]
9. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
10. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
11. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
Durbin AP; McArthur JH; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
Hum Vaccin; 2006; 2(6):255-60. PubMed ID: 17106267
[TBL] [Abstract][Full Text] [Related]
12. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis.
Angsubhakorn S; Yoksan S; Pradermwong A; Nitatpattana N; Sahaphong S; Bhamarapravati N
Southeast Asian J Trop Med Public Health; 1994 Sep; 25(3):554-9. PubMed ID: 7777925
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
[TBL] [Abstract][Full Text] [Related]
14. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
15. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N
Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173
[TBL] [Abstract][Full Text] [Related]
17. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
Robert Putnak J; Coller BA; Voss G; Vaughn DW; Clements D; Peters I; Bignami G; Houng HS; Chen RC; Barvir DA; Seriwatana J; Cayphas S; Garçon N; Gheysen D; Kanesa-Thasan N; McDonell M; Humphreys T; Eckels KH; Prieels JP; Innis BL
Vaccine; 2005 Aug; 23(35):4442-52. PubMed ID: 16005749
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.
Wright PF; Durbin AP; Whitehead SS; Ikizler MR; Henderson S; Blaney JE; Thumar B; Ankrah S; Rock MT; McKinney BA; Murphy BR; Schmidt AC
Am J Trop Med Hyg; 2009 Nov; 81(5):834-41. PubMed ID: 19861619
[TBL] [Abstract][Full Text] [Related]
20. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
